MYRIAD GENETICS INC
Ticker: 899923
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 202.70+6.3% | 190.70-4.8% | 200.40-2.6% | 205.70-3.5% | 213.10+8.8% | 195.90-8.2% | 213.30+0.9% | 211.50 |
| Total Income | 202.70+6.3% | 190.70-4.8% | 200.40-2.6% | 205.70-3.5% | 213.10+8.8% | 195.90-8.2% | 213.30+0.9% | 211.50 |
| EXPENSES | ||||||||
| Expenditure | 242.60+5.7% | 229.60-0.6% | 231.10+0.9% | 229.00-57.8% | 542.30+141.1% | 224.90-3.6% | 233.30-5.9% | 248.00 |
| Tax | 0.30-50.0% | 0.60 | 0.00-100.0% | 1.20+1300.0% | -0.10+99.7% | -29.30-3355.6% | 0.90+280.0% | -0.50 |
| PROFIT | ||||||||
| PBT | -43.60-2.3% | -42.60-24.9% | -34.10-30.2% | -26.20+92.1% | -330.60-1024.5% | -29.40-38.7% | -21.20+43.0% | -37.20 |
| Net Profit | -43.90-1.6% | -43.20-26.7% | -34.10-24.5% | -27.40+91.7% | -330.50-330400.0% | -0.10+99.5% | -22.10+39.8% | -36.70 |
| KEY METRICS | ||||||||
| OPM % | -19.68%+0.71pp | -20.40%-5.08pp | -15.32%-3.99pp | -11.33%+88.67pp | -100.00%-85.20pp | -14.80%-5.43pp | -9.38%+7.88pp | -17.26% |
| NPM % | -21.66%+0.99pp | -22.65%-5.64pp | -17.02%-3.70pp | -13.32%+86.68pp | -100.00%-99.95pp | -0.05%+10.31pp | -10.36%+6.99pp | -17.35% |
| EPS | -0.46+0.0% | -0.46-27.8% | -0.36-24.1% | -0.29+91.9% | -3.57 | 0.00+100.0% | -0.24+41.5% | -0.41 |
Corporate Events
Board MeetingMYGN
20266Nov
Board Meeting
Executive Retention Stock Option Awards approved for certain…
SEC Filing ↗ Board MeetingMYGN
20264Nov
Board Meeting
Myriad Genetics, Inc. to hold its third quarter 2026 earning…
SEC Filing ↗ Board MeetingMYGN
202616Sep
Board Meeting
Vishal Sikri promoted to Executive Vice President - Commerci…
SEC Filing ↗ Board MeetingMYGN
202630Jul
Board Meeting
Second Quarter 2026 Earnings Conference Call and Business Up…
SEC Filing ↗ Board MeetingMYGN
202617Jun
Board Meeting
Director Resignation — Daniel M. Skovronsky M.D., Ph.D. resi…
SEC Filing ↗ Board MeetingMYGN
20264Jun
Board Meeting
Myriad Genetics Inc. held its 2026 Annual Meeting of Stockho…
SEC Filing ↗ Board MeetingMYGN
20261Jun
Board Meeting
CTO Appointment — Raj Jampa appointed as Chief Technology Of…
SEC Filing ↗